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Background: Argentina has the sixth largest number of cumulative pediatric cases of acquired immunodeficiency 
syndrome (AIDS) in the Americas; therefore, this study was designed to characterize human immunodeficiency 
virus-l (HIV-l) infection in children in Buenos Aires, Argentina. 
Materials and Methods: Medical records of 389 children at risk and infected with HIV-l, an urban population 
followed by the AIDS Reference Center at the Hospital de Nifios “Dr. Ricardo Gutierrez” of Buenos Aires, from 
February 1990 to June 1997, were retrospectively reviewed. Mother-infant pairs were analyzed according to clinical 
and epidemiologic patterns. 
Results: Perinatal transmission occurred in 94.9% of the 389 cases classified as seroreverter’(n=104, 26.7%), 
exposed (n=64, 16.4%), asymptomatic (n=13,3.4%), and symptomatic patients (n=208, 53.5%); 132 patients met 
the Centers for Disease Control and Prevention (CDC) criteria for AIDS. The main maternal risk factor was sexual 
transmission 58.9% (73.4% of their sexual partners were injection drug users [IDU]). Among the AIDS patients, the 
most common AIDS-defining condition and death-related disease were severe bacterial infection and Pneumocystis 
carinii pneumonia, respectively. Death occurred in 51 of 221 HIV-infected children. Low CD4 was related to death 
(P < 0.001). Mortality was estimated for two periods: January 1990 to December 1995 (Gl) and January 1996 to 
May 1997 (G2). In Gl, 37 of 127 (29.1%) died compared with 14 of 154 (9.1%) in G2 (P=O.OOl). The median age of 
death was 10 months for Gl and 29 months for G2 (P=O.Ol). The 3-year survival rate was 72% for Gl and 87% for 
G2 (log rank P=O.O6). 
Conclusions: Intravenous drug use is the leading risk factor among parents of children exposed to HIV Infant 
mortality was related to age less than 12 months, low CD4 count, severe bacterial infection and E carinii pneumonia. 
In this study, I? carinii pneumonia prophylaxis and combined antiretroviral therapy routinely implemented since 
1996 has demonstrated a trend toward increased survival rates (P=O.O6) and a lower mortality rate (P=O.OOl). 
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In recent years, human immunodeficiency virus (HIV) 
infection and acquired immunodeficiency syndrome 
(AIDS) have become a major public health problem in 
many developing countries. Since 1989, the incidence of 
pediatric AIDS has been increasing in Argentina and 
throughout the world. 
The global HIV epidemic is far worse than 
previously thought, with about one in every 100 adults 
between the ages of 15 and 49 years infected; the 
developing world now bears more than 90% of the 
world’s HIV-AIDS burden. The Joint United Nations 
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Programme on HIV/AIDS (UNAIDS) and the World 
Health Organization (WHO) estimated that, by the end 
of 1997, 30.6 million people were infected with HIV. 
More than 40% are women; more than half are 
between 15 and 24 years of age; and most are unaware 
that they are infected. Around 16,000 new infections 
occurred every day in 1997, which means that half as 
many people were infected that year alone as have died 
in the whole epidemic. 
Pediatric data reveal perhaps the greatest gap 
between industrialized and developing countries. By the 
end of 1997, about 2.7 million children had died of 
AIDS and around 1.6 million children were orphaned 
by HIV Now AIDS is among the top 10 leading causes 
of death in children over 1 year of age.l 
Argentina ranks sixth in cumulative number of 
pediatric AIDS cases in the Americas after the United 
States, Brazil, Mexico, Puerto Rico, and Canada.2,3 Only 
154 cases of AIDS in adults were reported from 
Argentina as of December 1987; although 10,669 
cases were reported through June 1997,6% of them 
were pediatric cases. The overall rate of infection is 
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Figure 1. Cumulative numbers of HIV at risk and infected children between February 1990 and June 1997. 
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Figure 2. Modes of transmission of HIV among parents of perinatal cases. 
*Data were unavailable in 32 cases. IDU=injection drug user. 
5.4/100,000, but it is as high as 103.6/100,000 in some de Nifios “Dr. Ricardo Gutierrez” of Buenos Aires, 
cities, such as Buenos Aires.4 Argentina, from February 1990 to June 1997. 
Homosexual men were the first group of individ- 
uals identified to be infected in the region, but a rapid 
spread of HIV infection among females and drug injec- 
tors was detected in the past years, so actually 44% of 
AIDS cases occur in the intravenous drug users (male 
to female ratio, 3.8:1).4 Perinatally acquired HIV infec- 
tion accounts for almost 90% of all HIV infected 
children in Argentina, which is similar to other reported 
rates (Europe 78%, United States 90%).5,6 
MATERIALS AND METHODS 
Few data are available from Latin America; there- 
fore, the present retrospective study was performed to 
determine the clinical and epidemiologic aspects of 389 
at-risk and infected children seen at the Hospital 
The medical records of 389 at-risk and HIV-l-infected 
children followed by the AIDS Reference Center, 
Division of Pediatric Infectious Disease at the Hospital 
de Nifios “Dr. Ricardo Gutierrez” of Buenos Aires, 
Argentina, from February 1990 to June 1997 were 
retrospectively reviewed. This hospital is a reference 
pediatric center that serves a population of 435,000 out- 
patients per year and 12,500 inpatients referred from a 
primarily urban population of Buenos Aires and 
greater Buenos Aires. This area comprises 15,000,000 
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Figure 3. Classification of study population. 
(*132/208 symptomatic HIV-positive patients fit the CDC AIDS-defining classification system.) 
inhabitants, almost 33% of the total Argentine who had had no other laboratory evidence of infection 
population. and no AIDS-defining condition. 
Data collected from patients included age, gender, 
and classification of HIV infection, clinical status, and 
medications used for prophylaxis against opportunistic 
infections, and antiretroviral treatment. Patients were 
classified according to the 1994 Centers for Disease 
Control and Prevention (CDC) revised pediatric 
classification system. Infection with HIV in children was 
determined using the CDC definition for infection; 
AIDS cases were determined using the CDC AIDS 
case definition.7,8 
Both at-risk and HIV-infected children were 
followed monthly, including complete physical examin- 
ation, social services for families, early recognition and 
treatment of infection and HIV-associated patterns, and 
laboratory tests. 
Immunologic test 
The diagnostic criteria for HIV infection differed 
depending on the age of the child. In infants and 
children under 18 months of age, infection was defined 
by either culture of HIV-l from peripheral blood 
lymphocytes or two or more positive DNA polymerase 
chain reaction (PCR) or p24 antigen assays, or the 
presence of illness meeting the CDC criteria for diag- 
nosis of AIDS. 
Lymphocyte subsets and serum immunoglobulins were 
done every six months in asymptomatic patients under 
18 months and every 3 months in symptomatic patients 
under 18 months of age. Normal CD4 values were as 
defined by CDC.9 
Clinical definitions 
Infection in children over 18 months of age was 
defined by one or more of the following: culture of the 
virus from peripheral blood lymphocytes, the presence 
of antibody by enzyme-linked immunosorbent assay 
(ELISA) and Western blot, or illness meeting the CDC 
criteria for AIDS. 
Severe bacterial infection (SBI) was defined as multiple 
or recurrent infections (any combination or at least two 
confirmed infections within a 2-y period) of the follow- 
ing types: sepsis, pneumonia, meningitis, bone or joint 
infection, or abscess of an internal organ or body cavity. 
Statistical analysis 
A seroreverter was defined as a child who was born 
to an HIV-infected mother and had been documented 
to have HIV-negative antibody (two or more negative 
enzyme immunoassay (EIA) tests performed at 6-18 
months of age or one negative EIA test after 18 months 
of age) or who had had negative results on two separate 
determinations of HIV-l culture or DNA PCR with at 
least one of them performed after 6 months of age, and 
Chi-squared test, Fisher exact test, and Wilcoxon two- 
sample test were used for analysis. Data are shown as 
frequencies or mean (standard deviation). Two-sample 
Z test was used when appropriate. The Mann-Whitney 
test was used to compare the differences between two 
continuous variables because of non-normality of the 
samples. All reported P-values are two-sided, and the 
P< 0.05 was selected as the level of significance. Survival 
analysis was done using the Kaplan-Meier method. 
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Figure 4. Survival rates: Gl 1990-1995 vs. G2: 1996-1997. Log rank test, P=O.O6. 
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Figure 5. Survival rates in P. carinii pneumonia: Gl 1990-1995 vs. G2: 1996-1997. Log rank test, P=O.Ol. 
RESULTS 
Demographic profile and risk factors 
From February 1990 to June 1997, the cumulative 
number of HIV-seropositive children was 389 (Figure 
l), with an increasing numbers of cases every year. 
Perinatal transmission accounted for 94.9% of the 
infected cases among whom 54% were male and 46% 
female. Most of the children (75%) were from low 
socioeconomic status. 
Parental risk factors, age, and clinical status 
Maternal 
Data from 389 infants at risk or infected with HIV who 
were born to 367 mothers were included in the analysis. 
Infection acquired through sexual contact with an 
infected partner was the most frequent maternal risk 
factor (216/367, X9%), followed by injection drug use 
(IDU) (118/367,32.1%); transfusion (g/367,2.2%), and 
others 25 of 367 (6.8%) (Figure 2). 
The mean age of mothers was 22.86 years (range, 
15-46 y); 19.5% were adolescents (~19 y). Of these 367 
women, 264 (72%) were asymptomatic, 103 (28%) were 
symptomatic mothers, and 31 died of AIDS. 
Paternal 
Intravenous drug use was the main risk factor for infec- 
tion in the fathers (245/335, 73.2%) of cases, followed 
by heterosexual contact (78/335,23.3%), and no identi- 
fied risk (12/335,3.65%) (see Figure 2). 
The mean age of the fathers was 23.94t-10.64 years 
(range, 15-52 y); 17% were younger than 19 years. Of 
335 fathers, 223 (66.6%) were asymptomatic and among 
the 112 who were ill, death has,occurred in 44 (39.3%). 
Clinical characteristics, pattern of disease and age of 
HIV infected children 
At the time of analysis the clinical status of the 389 
HIV-l-positive children, using CDC classification system, 
was 104 (26.7%) seroreverted, 64 (16.4%) indeter- 
minate status, and 13 (3.4%) were HIV-positive but 
asymptomatic and 208 (53.5%) were symptomatic. 
Among the 208 symptomatic patients, 132 fit the CDC 
case definition for AIDS (Figure 3). 
The most frequent clinical findings detected in the 
208 symptomatic patients were lymphadenopathy 
(75%), hepatomegaly (61.5%), splenomegaly (57%), 
diarrhea (52%), persistent oral thrush (50%), failure to 
thrive (44.7%), and parotitis (25.4%). 
Increased IgG was detected in 73.5% of infected 
patients; IgM was elevated in 70% and IgA in 57.2% of 
cases. A decrease in CD4 cell count was present in 68% 
of infected patients. 
The AIDS-indicator diseases that were found in 
132 patients with AIDS are shown in Table 1. At the 
time of diagnosis of an AIDS-indicator disease, 54.5% 
of patients were less than 12 months of age, 61 cases 
had more than one AIDS-defining illness. 
Mortality and survival related factors 
The overall mortality rate in pediatric HIV-infected 
patients was 23.1% (51/221). It was related to SBI in 16 
(31.4%) R carinii pneumonia in 11 (21.6%), C&IV in 4 
(7.8%), wasting syndrome in 4 (7.8%), HIV encepha- 
lopathy in 3 (6%), and other causes in 4 (7.8%) patients. 
Death was not related to AIDS in 9 patients (17.6%). 
The mean age at death was 25.5k26.3 months. 
When l? carinii pneumonia was compared with other 
indicator diseases, there was a statistical difference in 
age at death (P=O.OOl): 35.5k28.6 months for SBI and 
7.5k10.4 months for P carinii pneumonia (Table 2). 
Statistically significant factors related to mortality 
in this study population were age less than 12 months 
at onset of HIV-related symptoms; the presence of an 
AIDS-defining illness, especially P carinii pneumonia 
and SBI (P=O.OOl); and CD4 percentage below 20%. 
The mean CD4 percentage for patients who had died 
was 14.16?14.9% and 23.5t17.8% for surviving 
patients (P<O.OOl) (Table 3). 
From January 1996, l? carinii prophylaxis was pre- 
scribed for all perinatal patients less than 1 year of 
age (n=9) and therapy with two drugs, zidovudine 
(AZT) and didanosine (ddI), was started in all infected 
patients. Mortality was estimated for two periods, Jan- 
uary 1990 to December 1995 (Gl) and January 1996 to 
June 1997 (G2). In the first period, Gl, 37 of 127 
patients had died, which represents a mortality rate of 
29.1%, compared with 14 of 154 patients (9.1%) in G2 
(P=O.OOl). The mean age at death was 19.9t21.1 mo 
for Gl, and 35.5229 mo for G2 (P=O.Ol) (Table 4). 
Overall survival rate at 3 years was 72% for Gl and 
87% for G2 (Kaplan-Meier curves; log rank, P=O.O6) 
(Figure 4). A trend was found in children with I? carinii 
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pneumonia toward longer survival comparing the 
periods: Gl, 59%, and G2,90% (Figure 5). 
DISCUSSION 
13 
two 
The vertical transmission of HIV infection and the 
clinical course and management of pediatric AIDS have 
been reviewed in the United States. Transmissions 
from mother to child have been reported in 13 to 39% 
Table 1. AIDS-defining illnesses among 132 pediatric patients* 
Disease cases 
Disease n=226 (%) 
Severe bacterial infection (SBI) 82 (36) 
Pneumocystis carinii pneumonia (PCP) 79 (35) 
Cryptosporidiosis 18 
Lymphoid interstitial pneumonitis (LIP) 16 I;; 
Encephalopathy 13 6) 
Wasting syndrome 6 (3) 
Disseminated cytomegalovirus (CMV) 5 (2) 
Other 7 (3) 
*71 patients had one indicator disease, 16 had three, 35 had two, and 10 
had four indicator diseases. 
Table 2. Age at death among the 51 patients with an AIDS- 
indicator disease 
Age at death 
AIDS-indicator disease Months *SD Median (mo) 
Severe bacterial infection 35.5k28.6 29.5 
Pneumocystis carinii pneumonia 7.5k10.4 4.0* 
Wasting syndrome 42.Ok24.0 55.0 
Encephalopathy 1 l.Ok7.0 11.0 
Cytomegalovirus 9.Ok6.0 7.5 
Mean age at death: 25.5k26.3 mo. *Pcarinii pneumonia vs. other 
indicator diseases, P=O.OOl. 
Table 3. Factors related to mortality 
Percentage Odds ratio RR P 
Age 
<I2 mo 
rl2 mo 
CD4 
<20% 
>20% 
AIDS 
Non AIDS 
PCP+SBI 
Other 01 
47.05 6.8 4.05 <0.0001 
13.2 
30.2 3.04 2.57 0.001 
9.9 
37.1 25.68 16.5 <0.0001 
2.2 
33.3 2.9 2.01 0.001 
14.7 
Table 4. Comparative mortality between Gl: 1990-1995 and 
G2: 1996-l 997 
(w&m) (m&xv) P 
Mortality rate 29.1% 9.1% 0.001 
Age at death 
(mean SD) 19.9221.2 mo 35.5*29 mo 0.01 
Median age at death 10 mo 29 mo 
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of infants born to HIV-infected women. Published 
estimates a range of 13 to 20% in Europe, 28 to 52% in 
Africa and 13 to 39% in the United States.l”-13 
It was not possible to estimate the transmission rate 
in the present study population because the hospital is a 
referral center in Buenos Aires, without a maternity 
ward, and children are referred from other centers 
because of severe illness and clinical findings. This intro- 
duces bias into these study data. 
Most of the 389 HIV-positive patients acquired 
their infection perinatally, whereas the remaining 
acquired their infection parenterally from unscreened 
blood transfusion before 1988, when donor screening 
for HIV antibody began in Argentina. 
The predominant mode of transmission for women 
in the United States during the past years has been the 
sharing of needles during parenteral use of illicit drugs. 
This mode of transmission continues to be problematic; 
however, heterosexual contact is currently the most 
common source of infection. The partners of these 
women are often infected with HIV as a result of IDU, 
and they transmit the virus to the women through 
sexual contact.14J5 
Risk factors for HIV infection in mothers included 
sexual contact with an HIV-infected man in 59% of 
cases. Intravenous drug use accounted for 32% of 
infection in women and in 72% of their male sexual 
partners. Thus the epidemiologic pattern was more 
similar to that of the United States or Europe rather 
than to that seen in Africa or other developing coun- 
tries, including Latin America, where heterosexual 
transmission is the dominant route of HIV infec- 
tion 16-22 
There has been a remarkable increase in reported 
AIDS cases among women in Argentina from 1.1% in 
1987 to 17.4% in 1994,80% of them are of childbearing 
age, with a mean age of 24 years.5 In this study, the 
majority of the mothers were young, and since 28% 
have AIDS and 30% of them have died, this implies 
that HIV infection was acquired during adolescence. 
In addition, sexual behavior and drug use patterns 
established during adolescence would affect an 
individual’s risk of HIV infection for years to come, and 
this should be considered in order to develop a success- 
ful prevention program. 
These data are important in the development of 
preventive measures for young people, ideally, the need 
for counselling and testing of all pregnant women 
should be recognized by all health care providers 
in Argentina so that zidovudine prophylaxis can be 
offered, which has shown a lower rate of vertical 
transmission.23-26 
The clinical manifestation of HIV-related symp- 
toms is a combination of persistent generalized lymph- 
adenopathy, hepatomegaly, and splenomegaly. Results 
of this study more closely resemble those reported in 
Europe and United States than results of studies 
in Africa. where chronic diarrhea and failure to 
thrive, with the development of severe protein-energy 
malnutrition, represent the principal clinical presenta- 
tion of HIV-l infection.5,27-31 
Among 3665 perinatally acquired AIDS cases 
reported from 1982 through 1992 in the United States, 
the most common AIDS-indicator diseases were P. 
carinii pneumonia (35%), lymphoid interstitial pneu- 
monitis (25%), and recurrent severe bacterial infections 
(19%).17 In the present study population, SBI, l? carinii 
pneumonia, and cryptosporidiosis were the principal 
marker diseases. 
Bacterial infections have a substantial degree of 
morbidity associated with pediatric AIDS. This study 
showed an increased frequency of SBI, representing a 
significantly greater impact on morbidity and mortality 
in the patients than reported in other studies.32-34 In 
this study population, P. carinii pneumonia was the 
principal cause of early mortality, as in most series 
already published, except for those among children in 
Africa and the Caribbean, where l? carinii pneumonia 
has a relatively lower incidence for both children and 
adults.35,36 It is not known if this pattern is attributable 
to epidemiologic differences, because of difficulties in 
establishing diagnosis, or because children succumb to 
an earlier death, related to other prevalent pathogens.13 
It was observed that survival of children with SBI 
was about 3 years, an interval much longer than the 
survival rate for P carinii pneumonia or HIV encepha- 
lopathy, but substantially shorter than that related to 
lymphoid interstitial pneumonia. Other reports confirm 
these findings.30,37 
Two modes of progression of HIV-l disease have 
been described in the pediatric population. Rapid 
progression is characterized by onset of symptoms 
before 12 months of age, severe immunodeficiency 
development, with severe opportunistic infections 
(most often P carinii pneumonia) or encephalopathy 
within the first year of life, usually with poor prognosis. 
It is because of the presentation of illness in this group 
of patients that l? carinii pneumonia prophylaxis is 
instituted early in life. Infants in this group constitute 
around 20% to 40% of patients; whereas the remaining 
60% to 70% of infected children have a form of disease 
that progresses more slowly and is more similar to that 
seen in adults.38-40 
In the present series, 55% of patients began with 
symptoms before 12 months of age, nevertheless, the 
authors do not think this finding was related to a differ- 
ent pattern, perhaps it was related to the fact that some 
patients were sent to the hospital because of severe ill- 
ness at early ages from other centers, and it constitutes 
a bias in the Whole evaluation. Coincidentally with the 
literature, the symptoms associated with poor prognosis 
were the presence of marker disease especially SBI and 
p carinii.pneumonia.27,28 
The availability of combined antiretroviral therapy 
and early medical intervention with prophylaxis and 
treatment of infections has altered somewhat the 
HIV infection in children of Argentina I Fall0 et al 15 
natural history of HIV infection and increased the 
survival time of infected patients.41 In the first years of 
the epidemic, most of the perinatally infected children 
cared for consisted of infants and young children with 
advanced HIV disease. The long incubation period from 
infection to symptom development in children was not 
yet recognized. During recent years, an increasing 
number of older children have been identified. Several 
reports have provided a better knowledge of the 
natural history of children with HIV infection.42,43 In 
1989, Nielsen and colleagues reported a cohort of 
children with a mean survival of 77 months.41 Krasinsky 
and co-workers reported a mean survival time of 67 
months for 95 perinatally infected children. In 1992, 
Tovo and co-workers reported a mean survival of 96.2 
months.37,44 
To evaluate differences in mortality and survival 
trends of the present study population observed in the 
past years, the authors analyzed two periods: 1990 to 
1995 and 1996 to 1997. From January 1996 a program of 
P. carinii pneumonia prophylaxis for all infected or 
exposed infants less than 1 year of age, born to HIV- 
infected women was implemented, independent of 
immunologic or clinical status and combined anti- 
retroviral therapy was routinely offered for all HIV- 
infected children. During this time a significant increase 
in survival time, and a decreased mortality rate was 
observed for the second period. 
Pediatric AIDS is a chronic infection and newer 
therapies are more effective. It is important to continue 
evaluating clinical, epidemiologic and laboratory vari- 
ables of the impact of pediatric HIV disease, to develop 
new strategies of treatment, prevention, and care for 
patients. 
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